|
PE20090717A1
(es)
*
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US7928140B2
(en)
|
2007-08-02 |
2011-04-19 |
Amgen Inc. |
Benzothiazole PI3 kinase modulators for cancer treatment
|
|
JP2011500823A
(ja)
*
|
2007-10-22 |
2011-01-06 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
|
|
PE20091268A1
(es)
|
2007-12-19 |
2009-09-19 |
Amgen Inc |
Derivados heterociclicos como inhibidores de pi3 quinasa
|
|
JP5599783B2
(ja)
|
2008-05-30 |
2014-10-01 |
アムジエン・インコーポレーテツド |
Ｐｉ３キナーゼの阻害薬
|
|
EP2298731A4
(en)
*
|
2008-06-25 |
2011-09-21 |
Takeda Pharmaceutical |
AMIDE COMPOUND
|
|
JP5564045B2
(ja)
|
2008-09-02 |
2014-07-30 |
ノバルティス アーゲー |
二環式キナーゼ阻害剤
|
|
JP5702293B2
(ja)
|
2008-11-10 |
2015-04-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
WO2010059549A1
(en)
*
|
2008-11-18 |
2010-05-27 |
Glaxosmithkline Llc |
Prolyl hydroxylase inhibitors
|
|
BRPI0924084B1
(pt)
|
2008-12-19 |
2021-12-21 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina e composição farmacêutica que os compreende
|
|
WO2010075380A1
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
WO2010075376A2
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
US8741917B2
(en)
|
2009-01-15 |
2014-06-03 |
Rutgers, The State University Of New Jersey |
Benzo [C] phenanthridines as antimicrobial agents
|
|
ES2548571T3
(es)
|
2009-04-02 |
2015-10-19 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii |
Derivados de imidazo[2,1-b][1,3,4]tiadiazol
|
|
EP2419404B1
(en)
|
2009-04-15 |
2015-11-04 |
AbbVie Inc. |
Anti-viral compounds
|
|
US20120059026A1
(en)
|
2009-04-30 |
2012-03-08 |
University Of Medicine And Dentistry Of New Jersey |
Antimicrobial agents
|
|
BRPI1010600A2
(pt)
|
2009-05-15 |
2016-03-15 |
Novartis Ag |
aril piridina como inibidores de aldosterona sintase
|
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
|
MX2011013667A
(es)
*
|
2009-06-25 |
2012-03-06 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
WO2011021678A1
(ja)
*
|
2009-08-21 |
2011-02-24 |
武田薬品工業株式会社 |
縮合複素環化合物
|
|
ES2900504T3
(es)
|
2009-09-03 |
2022-03-17 |
Bristol Myers Squibb Co |
Quinazolinas como inhibidores de los canales iónicos de potasio
|
|
RU2595718C2
(ru)
*
|
2009-09-09 |
2016-08-27 |
Селджен Авиломикс Рисерч,Инк. |
Ингибиторы pi3-киназы и их применение
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
AU2010298020B8
(en)
*
|
2009-09-28 |
2013-10-10 |
Glaxosmithkline Llc |
Combination
|
|
AU2010307043C1
(en)
*
|
2009-10-12 |
2014-03-13 |
Glaxosmithkline Llc |
Combination
|
|
WO2011051958A1
(en)
|
2009-10-30 |
2011-05-05 |
E.I. Du Pont De Nemours And Company |
Fungicidal pyrazolones
|
|
AU2010339456A1
(en)
|
2009-12-30 |
2012-07-05 |
Celgene Avilomics Research, Inc. |
Ligand-directed covalent modification of protein
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
EP2569287B1
(en)
|
2010-05-12 |
2014-07-09 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
WO2011143422A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
2 -aminopyridine derivatives useful as inhibitors of atr kinase
|
|
AU2011253025A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2011156626A1
(en)
|
2010-06-09 |
2011-12-15 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
WO2011163527A1
(en)
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
CA2803890A1
(en)
|
2010-06-25 |
2011-12-29 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
WO2012016082A1
(en)
*
|
2010-07-30 |
2012-02-02 |
Oncotherapy Science, Inc. |
Quinoline derivatives and melk inhibitors containing the same
|
|
JP2013536192A
(ja)
*
|
2010-08-09 |
2013-09-19 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
組み合わせ
|
|
WO2012068468A1
(en)
*
|
2010-11-19 |
2012-05-24 |
Glaxosmithkline Llc |
Method of treatment with braf inhibitor
|
|
EP2640366A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
WO2012068106A2
(en)
|
2010-11-15 |
2012-05-24 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
|
US20130317037A1
(en)
*
|
2010-11-16 |
2013-11-28 |
Glaxosmithkline Intellectual Property Development Limited |
Method of administration and treatment
|
|
US20140378436A9
(en)
|
2010-11-24 |
2014-12-25 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
|
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
WO2012122011A2
(en)
|
2011-03-04 |
2012-09-13 |
Glaxosmithkline Llc |
Amino-quinolines as kinase inhibitors
|
|
WO2012122370A2
(en)
*
|
2011-03-08 |
2012-09-13 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
CN102718745A
(zh)
*
|
2011-03-30 |
2012-10-10 |
中国科学院上海药物研究所 |
新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
|
|
WO2012138938A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
|
UY34044A
(es)
*
|
2011-04-29 |
2012-11-30 |
Sanofi Sa |
Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor
|
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
EP2723745A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
TWI547494B
(zh)
|
2011-08-18 |
2016-09-01 |
葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之胺基喹唑啉類
|
|
MX2014003796A
(es)
|
2011-09-30 |
2015-01-16 |
Vertex Pharma |
Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
IN2014CN02501A
(enExample)
|
2011-09-30 |
2015-06-26 |
Vertex Pharma |
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP6170060B2
(ja)
|
2011-11-04 |
2017-07-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
新規アリール−キノリン誘導体
|
|
EP2776421A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
EP2776422A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
JP6117235B2
(ja)
|
2011-12-15 |
2017-04-19 |
ノバルティス アーゲー |
Ｐｉ３ｋの活性または機能の阻害剤の使用
|
|
WO2013106756A2
(en)
|
2012-01-13 |
2013-07-18 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
AU2013218149A1
(en)
|
2012-02-06 |
2014-07-24 |
Glaxosmithkline Intellectual Property (No.2) Limited |
PI3K inhibitors for treating cough
|
|
BR112014018106A2
(pt)
*
|
2012-02-06 |
2017-06-27 |
Glaxosmithkline Ip No 2 Ltd |
composto, uso de um composto, e, método para tratar uma doença fibrótica
|
|
AU2013235038A1
(en)
|
2012-03-21 |
2014-10-09 |
Malvika Kaul |
Antimicrobial agents
|
|
US20140044802A1
(en)
|
2012-04-05 |
2014-02-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
and combination therapies thereof
|
|
IN2014DN11205A
(enExample)
|
2012-06-20 |
2015-10-02 |
Eutropics Pharmaceuticals Inc |
|
|
TW201425307A
(zh)
|
2012-09-13 |
2014-07-01 |
Glaxosmithkline Llc |
作為激酶抑制劑之胺基－喹啉類
|
|
TWI592417B
(zh)
|
2012-09-13 |
2017-07-21 |
葛蘭素史克智慧財產發展有限公司 |
胺基喹唑啉激酶抑制劑之前藥
|
|
CN103497177B
(zh)
*
|
2012-09-29 |
2017-03-22 |
天津滨江药物研发有限公司 |
作为c‑Met抑制剂的氨基芳香杂环类化合物及其制备方法
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
CN103788071A
(zh)
*
|
2012-11-01 |
2014-05-14 |
中国人民解放军第二军医大学 |
N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途
|
|
US20160038503A1
(en)
|
2012-11-21 |
2016-02-11 |
David Richard |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
|
|
SMT202000713T1
(it)
|
2012-12-07 |
2021-03-15 |
Vertex Pharma |
Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
|
|
TWI630203B
(zh)
|
2013-02-21 |
2018-07-21 |
葛蘭素史克智慧財產發展有限公司 |
做為激酶抑制劑的喹唑啉類
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
CN104098542A
(zh)
*
|
2013-04-11 |
2014-10-15 |
苏州朗信医药科技有限公司 |
一种6-溴代-4-(4-吡嗪基)喹啉的制备方法
|
|
US10732182B2
(en)
|
2013-08-01 |
2020-08-04 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
|
EP3046921A4
(en)
|
2013-09-22 |
2017-02-22 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds and methods of use
|
|
CN104557955B
(zh)
*
|
2013-10-23 |
2017-05-03 |
上海汇伦生命科技有限公司 |
作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
|
|
US10640803B2
(en)
|
2013-10-30 |
2020-05-05 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
|
US9458150B2
(en)
|
2013-11-08 |
2016-10-04 |
Rutgers, The State University Of New Jersey |
Antimicrobial agents
|
|
CN105764514B
(zh)
*
|
2013-11-27 |
2019-07-12 |
圣诺康生命科学公司 |
作为tam族激酶抑制剂的氨基吡啶衍生物
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
EP4019518A1
(en)
|
2014-02-28 |
2022-06-29 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
CN104922116B
(zh)
*
|
2014-03-23 |
2020-08-11 |
上海诗丹德生物技术有限公司 |
甲基丙烯酰基苯并咪唑酮衍生物的用途
|
|
NO2714752T3
(enExample)
*
|
2014-05-08 |
2018-04-21 |
|
|
|
CN107074863B
(zh)
|
2014-06-05 |
2019-12-03 |
沃泰克斯药物股份有限公司 |
Atr激酶抑制剂的制备方法及其不同的固体形式
|
|
PL3157566T3
(pl)
|
2014-06-17 |
2019-10-31 |
Vertex Pharma |
Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
|
|
BR112016029825B1
(pt)
|
2014-06-17 |
2020-10-27 |
Cisen Pharmaceutical Co., Ltd. |
composto
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
|
WO2016025918A1
(en)
|
2014-08-15 |
2016-02-18 |
Janssen Pharmaceuticals, Inc. |
Pyrazoles
|
|
US9981950B2
(en)
|
2014-08-15 |
2018-05-29 |
Janssen Pharmaceuticals, Inc. |
Triazoles as NR2B receptor inhibitors
|
|
KR102754019B1
(ko)
|
2014-10-29 |
2025-01-14 |
바이시클러드 리미티드 |
Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
|
|
ES2930585T3
(es)
|
2015-02-27 |
2022-12-19 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
|
CN104961725B
(zh)
*
|
2015-06-18 |
2017-04-19 |
浙江大学 |
4‑α,β不饱和酰胺基喹啉类化合物及制备和应用
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
BR112018000468A2
(pt)
*
|
2015-07-09 |
2018-09-18 |
Janssen Pharmaceutica Nv |
4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
|
|
KR20180030913A
(ko)
*
|
2015-07-30 |
2018-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
아릴 치환된 비시클릭 헤테로아릴 화합물
|
|
US10329257B2
(en)
*
|
2015-08-13 |
2019-06-25 |
The Broad Institute, Inc. |
Compositions and methods for treating tuberculosis
|
|
JP6802263B2
(ja)
|
2015-09-02 |
2020-12-16 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
EP3347340A4
(en)
|
2015-09-08 |
2019-01-23 |
Monash University |
LYMPHENLEITUNGSPRODRUGS
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEINE INHIBITORS AND USE THEREOF
|
|
TWI713655B
(zh)
*
|
2015-12-16 |
2020-12-21 |
大陸商上海嘉坦醫藥科技有限公司 |
吡啶並[1,2-a]嘧啶酮類似物的晶型及其製備方法和中間體
|
|
MA44008A
(fr)
|
2016-02-10 |
2018-12-19 |
Janssen Pharmaceutica Nv |
1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
|
|
CN109195957A
(zh)
|
2016-02-25 |
2019-01-11 |
塔克西斯医药股份有限公司 |
合成方法和中间体
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
EP3426244B1
(en)
|
2016-03-09 |
2023-06-07 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
CA3027500A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
|
AU2017312970B2
(en)
*
|
2016-08-16 |
2021-08-12 |
Merck Patent Gmbh |
2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
|
|
TW201819376A
(zh)
|
2016-10-06 |
2018-06-01 |
比利時商健生藥品公司 |
經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
|
|
CN115448916B
(zh)
|
2016-10-14 |
2026-04-28 |
武田药品工业株式会社 |
Tyk2抑制剂及其用途
|
|
JP7082120B2
(ja)
|
2016-10-21 |
2022-06-07 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
CN106580986B
(zh)
*
|
2016-11-28 |
2017-09-15 |
王保亮 |
一种治疗少弱精子症的药物组合物
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US20180153922A1
(en)
|
2016-12-06 |
2018-06-07 |
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery |
Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
|
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
|
AU2017389818B2
(en)
*
|
2016-12-26 |
2022-04-07 |
Institute Of Materia Medica, Chinese Academy Of Medical Sciences |
Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
|
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
TWI868528B
(zh)
|
2017-03-08 |
2025-01-01 |
日商武田藥品工業股份有限公司 |
Ｔｙｋ２抑制劑之生產方法
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
CA3058183A1
(en)
|
2017-03-30 |
2018-10-04 |
Taxis Pharmaceuticals, Inc. |
Synthetic processes and synthetic intermediates towardthe production of txa709
|
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
|
TWI776886B
(zh)
|
2017-04-26 |
2022-09-11 |
美商奈維特製藥公司 |
Sestrin-gator2交互作用之調節劑及其用途
|
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AU2018269947B2
(en)
*
|
2017-05-15 |
2021-10-14 |
The Regents Of The University Of Michigan |
Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
|
|
CN111032678A
(zh)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
具有可检测部分的双环肽配体和其用途
|
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
ES2926195T3
(es)
|
2017-08-04 |
2022-10-24 |
Bicycletx Ltd |
Ligandos peptídicos bicíclicos específicos de CD137
|
|
EP3668550A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
CN107793404A
(zh)
*
|
2017-11-07 |
2018-03-13 |
全椒先奇医药科技有限公司 |
一种治疗缺血性脑损伤药物组合物及其应用
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP4616913A3
(en)
|
2018-01-29 |
2025-12-10 |
Merck Patent GmbH |
Gcn2 inhibitors and uses thereof
|
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
AU2019224659A1
(en)
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
EP3759086A1
(en)
|
2018-02-27 |
2021-01-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
MD3762368T2
(ro)
|
2018-03-08 |
2022-07-31 |
Incyte Corp |
Compuși diol aminopirazină ca inhibitori ai PI3K-Y
|
|
EP3774732A4
(en)
|
2018-04-04 |
2022-02-09 |
Janssen Pharmaceutica NV |
PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
|
|
HUE067936T2
(hu)
|
2018-04-24 |
2024-11-28 |
Merck Patent Gmbh |
Proliferáció-gátló vegyületek és alkalmazásuk
|
|
WO2019209757A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
EP3807248A4
(en)
*
|
2018-05-29 |
2021-10-27 |
Council of Scientific and Industrial Research |
BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
|
|
EP3575305A1
(fr)
*
|
2018-05-31 |
2019-12-04 |
Biocidal Alternative Solutions |
Procédé de fabrication de composés comprenant un groupe fonctionnel oxazolopyridinones
|
|
CN113194752A
(zh)
|
2018-06-01 |
2021-07-30 |
康奈尔大学 |
Pi3k相关疾病或病症的组合疗法
|
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
KR102595520B1
(ko)
*
|
2018-07-05 |
2023-10-30 |
엘지디스플레이 주식회사 |
헤테로아릴기를 가진 벤즈아졸 유도체 및 이를 포함하는 유기전계발광소자
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CA3115088A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
JP7644002B2
(ja)
|
2018-10-24 |
2025-03-11 |
ナビター ファーマシューティカルズ， インコーポレイテッド |
多形化合物およびその使用
|
|
CN113271938A
(zh)
|
2018-11-30 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
CN113474045A
(zh)
|
2018-12-21 |
2021-10-01 |
拜斯科技术开发有限公司 |
Pd-l1特异性的双环肽配体
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
AU2020212001A1
(en)
|
2019-01-23 |
2021-07-22 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
WO2020243049A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Merck Sharp & Dohme Corp. |
Factor xi activation inhibitors
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
JP2022536773A
(ja)
|
2019-06-14 |
2022-08-18 |
ヤンセン ファーマシューティカ エヌ．ベー． |
置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
|
|
MX2021015511A
(es)
|
2019-06-14 |
2022-01-31 |
Janssen Pharmaceutica Nv |
Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
|
|
EP3982958A1
(en)
|
2019-06-14 |
2022-04-20 |
Janssen Pharmaceutica NV |
Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
|
|
CN113993583A
(zh)
|
2019-06-14 |
2022-01-28 |
詹森药业有限公司 |
取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
|
|
PH12021552839A1
(en)
|
2019-06-14 |
2022-10-03 |
Janssen Pharmaceutica Nv |
Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
|
|
CR20210580A
(es)
|
2019-06-14 |
2022-01-31 |
Janssen Pharmaceutica Nv |
Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
|
|
BR112021025132A2
(pt)
|
2019-06-14 |
2022-01-25 |
Janssen Pharmaceutica Nv |
Carbamatos de piridina e seu uso como moduladores do receptor glun2b
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CN115038688A
(zh)
|
2019-09-11 |
2022-09-09 |
文森雷生物科学股份有限公司 |
Usp30抑制剂及其用途
|
|
PH12022550605A1
(en)
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
|
EP4051259A4
(en)
|
2019-11-01 |
2023-11-22 |
Navitor Pharmaceuticals, Inc. |
METHOD OF TREATMENT USING A MMOC1 MODULATOR
|
|
BR112022010754A2
(pt)
|
2019-12-05 |
2022-08-23 |
Anakuria Therapeutics Inc |
Análogos de rapamicina e usos dos mesmos
|
|
EP4072591A4
(en)
|
2019-12-10 |
2024-06-05 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADER AND USES THEREOF
|
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
|
US12569485B2
(en)
|
2019-12-23 |
2026-03-10 |
Kymera Therapeutics, Inc. |
SMARCA inhibitors and uses thereof
|
|
AU2021217172A1
(en)
|
2020-02-05 |
2022-09-22 |
Monash University |
Lipid prodrugs of neurosteroids
|
|
MX2022010944A
(es)
|
2020-03-03 |
2022-11-09 |
Pic Therapeutics Inc |
Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
|
|
IL296451B2
(en)
|
2020-03-19 |
2026-05-01 |
Kymera Therapeutics Inc |
MDM2 joints and their uses
|
|
TWI904146B
(zh)
|
2020-03-31 |
2025-11-11 |
美商卡默森屈有限公司 |
使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CA3189761A1
(en)
|
2020-08-03 |
2022-02-10 |
Gemma Mudd |
Peptide-based linkers
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
JP2023546996A
(ja)
|
2020-10-23 |
2023-11-08 |
ニンバス クロソー， インコーポレイテッド |
Ｃｔｐｓ１阻害剤およびその使用
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
WO2022147465A1
(en)
|
2020-12-30 |
2022-07-07 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US20240156805A1
(en)
|
2021-02-16 |
2024-05-16 |
Ribotech Co., Ltd. |
Compound for inhibiting nonsense-mediated mrna decay
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
JP7710756B2
(ja)
*
|
2021-03-18 |
2025-07-22 |
蘇州国匡医葯科技有限公司 |
Ｃｔｌａ－４低分子分解剤及びその使用
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
EP4319756A4
(en)
|
2021-04-09 |
2025-02-26 |
Nimbus Clio, Inc. |
CBL-B MODULATORS AND USES THEREOF
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
CN115353512B
(zh)
*
|
2021-07-30 |
2025-07-08 |
上海翊石医药科技有限公司 |
一种杂环脲类化合物及其制备方法和用途
|
|
CN113416181B
(zh)
*
|
2021-08-02 |
2022-05-03 |
四川大学 |
喹唑啉类衍生物及其用途
|
|
TW202315621A
(zh)
|
2021-08-25 |
2023-04-16 |
美商皮克醫療公司 |
Ｅｉｆ４ｅ抑制劑及其用途
|
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
WO2023046182A1
(zh)
*
|
2021-09-27 |
2023-03-30 |
广州嘉越医药科技有限公司 |
一种吡啶并[1,2-a]嘧啶酮类化合物的应用
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
IL314437A
(en)
|
2022-01-31 |
2024-09-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
KR20250040894A
(ko)
|
2022-05-25 |
2025-03-25 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
|
CN117402146A
(zh)
*
|
2022-07-13 |
2024-01-16 |
武汉人福创新药物研发中心有限公司 |
杂环并苯环类化合物及其制备方法和用途
|
|
JP2025527248A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
|
|
JP2025527247A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
JP2025527250A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
EP4605089A1
(en)
*
|
2022-10-20 |
2025-08-27 |
Mekanistic Therapeutics LLC |
Compounds useful in modulating egfr and pi3k
|
|
TW202430148A
(zh)
|
2022-11-22 |
2024-08-01 |
美商皮克醫療公司 |
ｅＩＦ４Ｅ抑制劑及其用途
|
|
CN116239594B
(zh)
*
|
2023-03-05 |
2023-09-22 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
6-(咪唑并[1,2-a]吡啶-6-基)喹唑啉衍生物及用途
|
|
EP4615455A2
(en)
|
2023-06-23 |
2025-09-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2025045915A1
(en)
*
|
2023-08-29 |
2025-03-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods for inducing muscle hypertrophy
|
|
AU2024344754A1
(en)
|
2023-09-21 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
CN118126038B
(zh)
*
|
2024-05-08 |
2024-07-12 |
烟台大学 |
吡唑并吡啶类衍生物及其制备方法和应用
|